Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2026)
Amneal Pharmaceuticals has reported Receivables over the past 9 years, most recently at $24.2 million for Q4 2025.
- For Q4 2025, Receivables rose 1184.55% year-over-year to $24.2 million; the TTM value through Dec 2025 reached $24.2 million, up 1184.55%, while the annual FY2025 figure was $24.2 million, 1184.55% up from the prior year.
- Receivables for Q4 2025 was $24.2 million at Amneal Pharmaceuticals, down from $1.5 billion in the prior quarter.
- Over five years, Receivables peaked at $1.5 billion in Q3 2025 and troughed at $1.9 million in Q4 2024.
- A 5-year average of $701.9 million and a median of $751.0 million in 2022 define the central range for Receivables.
- Biggest five-year swings in Receivables: plummeted 99.34% in 2024 and later skyrocketed 18463.62% in 2025.
- Year by year, Receivables stood at $663.8 million in 2021, then plummeted by 95.01% to $33.1 million in 2022, then plummeted by 93.36% to $2.2 million in 2023, then decreased by 14.4% to $1.9 million in 2024, then skyrocketed by 1184.55% to $24.2 million in 2025.
- Business Quant data shows Receivables for AMRX at $24.2 million in Q4 2025, $1.5 billion in Q3 2025, and $811.4 million in Q2 2025.